Trial intelligence / Profile preview

Baricitinib vs etanercept on ultrasound-assessed synovitis in methotrexate inadequate-response rheumatoid arthritis

DRKS00027537Phase 4Recruiting

Sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Start
Mar 2023
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
6
01

Overview

Phase 4, randomised, open-label trial in rheumatoid arthritis (RA) comparing Baricitinib monotherapy, Baricitinib plus methotrexate and Etanercept plus methotrexate (3 arms). Started Mar 2023; status: recruiting.

02

Drugs

baricitinibetanerceptmethotrexate
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on DRKS00027537.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on DRKS00027537.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call